《Table 1 Representative Populist Parties in European Countries12\n\t\t\t\t\t\t13》
本系列图表出处文件名:随高清版一同展现
《欧洲对“一带一路”建设的保护主义立场及影响(英文)》
The implementation of investment security review by the EU and its member states is not simply for preventing the loss of key technological know-how.There are multi-dimensional reasons behind it.Among them,the growing protectionist mentality is the primary one.European powers including Germany,Spain and Italy are deeply influenced by populism and the far right.Protectionism has been growing gradually and gained critical influence in the public opinion,which has imposed significant pressure on ruling parties(see Table 1).In addition,the United States has great influence on Europe’s protectionist policies.Trump’s coming to power has greatly encouraged the European populist forces.The US has also been actively promoting practices of strengthened market protection,and working in concert with Europe to build a security review mechanism for foreign investors.Affected by major European countries,some new EU member states have changed their attitudes.Poland,Slovakia and the Czech Republic have cautiously or passively responded China’s investment in areas such as highways,electric power and hydropower construction projects.It was not only because of the pressure imposed by the EU’s big powers,but also due to the rising influence of right-wing populist parties in Central and Eastern European countries and the subsequent emerging doubts from domestic public opinion and media about Chinese investment.The screening of Chinese investment involves a number of elements,including protecting the EU/Europe’s national interests,maintaining European core technologies,and catering to the extreme political atmosphere in Europe.
图表编号 | XD008358300 严禁用于非法目的 |
---|---|
绘制时间 | |
作者 | 刘作奎 |
绘制单位 | the Institute of European Studies, Chinese Academy of Social Sciences (CASS) |
更多格式 | 高清、无水印(增值服务) |
查看“Table 1 Representative Populist Parties in European Countries12\n\t\t\t\t\t\t13”的人还看了
- Table 5Herbal drugs from TCM included in the European Pharmacopoeia (Section 5.22 of the European Pharmacopoeia provides